Stock Events

Stock Events

Allakos 

$0.33
39
-$0-0.06% Wednesday 19:59

Statistics

Day High
0.33
Day Low
0.33
52W High
1.56
52W Low
0.22
Volume
724,800
Avg. Volume
1,145,449
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

29
MAY
Dividend Payment
Increased
 
14
AUG
Dividend Ex
Estimated
 
28
AUG
Dividend Payment
Estimated
 
13
NOV
Dividend Ex
Estimated
 
27
NOV
Dividend Payment
Estimated
 
12
FEB 27
Dividend Ex
Estimated
 

Dividends

0%Dividend Yield
May 26
$0.02
Feb 26
$0.02
Nov 25
$0.02
Aug 25
$0.02
May 25
$0.02
10Y Growth
N/A
5Y Growth
-2.39%
3Y Growth
0.81%
1Y Growth
-0.04%

Earnings

6AugExpected
Q1 2024
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
-0.75
-0.5
-0.25
0
Expected EPS
-0.16978020000000002
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-115.82MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ALLK. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap66.98B
Regeneron Pharmaceuticals competes in the biotech space, focusing on treatments that could overlap with Allakos' therapeutic areas, including inflammatory diseases.
Vertex Pharmaceuticals
VRTX
Mkt Cap110.28B
Vertex Pharmaceuticals is involved in creating treatments for autoimmune diseases and other chronic conditions, potentially competing with Allakos' drug development focus.
Gilead Sciences
GILD
Mkt Cap166.82B
Gilead Sciences operates in the biopharmaceutical field, developing drugs that could compete with Allakos' portfolio, especially in areas like immunology.
Abbvie
ABBV
Mkt Cap381.1B
AbbVie has a broad range of biopharmaceutical products that target similar therapeutic areas as Allakos, including autoimmune and inflammatory diseases.
AMGEN
AMGN
Mkt Cap183.12B
Amgen focuses on human therapeutics, with products that could compete in the same markets as Allakos, particularly in inflammation and autoimmunity.
Biogen
BIIB
Mkt Cap28.61B
Biogen's focus on advanced therapies for treating autoimmune disorders places it in direct competition with Allakos' research and development efforts.
Astrazeneca
AZN
Mkt Cap290.06B
AstraZeneca, with its wide range of treatments for various diseases, including those related to inflammation and autoimmunity, competes in similar therapeutic areas as Allakos.
Novartis
NVS
Mkt Cap290.05B
Novartis offers a broad portfolio of healthcare products, including treatments for autoimmune diseases, directly competing with Allakos' therapeutic targets.
Sanofi
SNY
Mkt Cap105.85B
Sanofi operates globally in the pharmaceutical sector, with a focus on treatments for chronic diseases, including those in Allakos' interest areas.
Pfizer
PFE
Mkt Cap147.62B
Pfizer's extensive research and development in biopharmaceuticals, including drugs for inflammatory and autoimmune diseases, makes it a competitor to Allakos.

About

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.
Show more...
CEO
Dr. Robert Alexander Ph.D.
Employees
131
Country
United States
ISIN
US01671P1003

Listings

0 Comments

Share your thoughts

FAQ

What is Allakos stock price today?▼
The current price of ALLK is $0.33 USD — it has decreased by -0.06% in the past 24 hours. Watch Allakos stock price performance more closely on the chart.
What is Allakos stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Allakos stocks are traded under the ticker ALLK.
What is Allakos revenue for the last year?▼
Allakos revenue for the last year amounts to 0 USD.
What is Allakos net income for the last year?▼
ALLK net income for the last year is -115.82M USD.
How many employees does Allakos have?▼
As of May 26, 2026, the company has 131 employees.
In which sector is Allakos located?▼
Allakos operates in the Health & Wellness sector.
When did Allakos complete a stock split?▼
Allakos has not had any recent stock splits.
Where is Allakos headquartered?▼
Allakos is headquartered in San Carlos, United States.